Trulicity ® (dulaglutid) injektion

För fullständig produktresumé för Trulicity® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Trulicity® (dulaglutid): Långsiktig säkerhet

Både dulaglutid 1,5 mg och dulaglutid 0,75 mg behandlingsdoser rapporterade mer behandlingsframkallande biverkningar än sitagliptinbehandlingsgruppen

Detailed Information

The AWARD-5 study was an adaptive, multicenter, randomized, 104-week, double-blind study that compared once-weekly dulaglutide 1.5 mg and dulaglutide 0.75 mg treatments with once-daily sitagliptin 100 mg and placebo in patients with T2DM inadequately controlled with metformin.1

Both dulaglutide 1.5 mg and dulaglutide 0.75 mg treatment doses reported more TEAEs than the sitagliptin treatment group due to greater incidence of GI AEs (Table 1. Adverse Events From Baseline to 104 Weeks in Patients Treated With Dulaglutide 1.5 mg, Dulaglutide 0.75 mg, or Sitagliptin 100 mg in the AWARD-5 Study ).1

A similar incidence of serious AEs was reported across treatment groups (Table 1. Adverse Events From Baseline to 104 Weeks in Patients Treated With Dulaglutide 1.5 mg, Dulaglutide 0.75 mg, or Sitagliptin 100 mg in the AWARD-5 Study ).1

Table 1. Adverse Events From Baseline to 104 Weeks in Patients Treated With Dulaglutide 1.5 mg, Dulaglutide 0.75 mg, or Sitagliptin 100 mg in the AWARD-5 Study 1,2

Variablea

DULA 1.5 mg
n=304

DULA 0.75 mg
n=302

SITA 100 mg
n=315

Treatment-emergent adverse events ≥1

259 (85)

255 (84)

242 (77)

Treatment-emergent GI adverse events

    Nausea

53 (17)

44 (15)

21 (7)

    Vomiting

41 (14)

25 (8)

11 (4)

    Diarrhea

49 (16)

36 (12)

18 (6)

    Abdominal pain

21 (7)

13 (4)

11 (4)

    Abdominal distention

13 (4)

15 (5)

3 (1)

    Dyspepsia

18 (6)

19 (6)

14 (4)

Pancreatic enzymes, median (Q1,Q3) [U/I]

    Lipase

6 (-1,14)

6 (-1,18)

3 (-2,9)

    Total amylase

6 (-1,15)

7 (-1,17)

3 (-3,12)

    p-Amylase

4 (0,9)

4 (0,11)

2 (-1,7)

Pancreatitis

0 (0) 

0 (0) 

2 (0.6)

Serious adverse events

36 (12)

23 (8)

32 (10)

    Infections and infestations

7 (2)

3 (1)

5 (2)

    Cardiac disorders

6 (2)

2 (1)

4 (1)

    Neoplasms

5 (2)

3 (1)

5 (2)

    Gastrointestinal events

4 (1)

2 (1)

4 (1)

    Renal/urinary disorders

5 (2)

2 (1)

0 (0)

Death

1 (<1)

0 (0)

2 (1)

Injection site reactions

4 (1.3)

3 (1.0)

3 (1.0)

Hypoglycemiab, mean (SD)

    Total

0.0 (0.2)

0.0 (0.5)

0.0 (0.3)

    Documented symptomatic

0.0 (0.1)

0.0 (0.5)

0.0 (0.3)

Discontinuation resulting from adverse events

63 (21)

64 (21)

65 (21)

Vital signs, LSM (SE)

    Systolic blood pressure, mmHg

-0.1 (0.8)

1.3 (0.8)

<0.1 (0.8)

    Diastolic blood pressure, mmHg

0.4 (0.5)

1.4 (0.5)

-0.4 (0.5)

    Pulse rate, beats/min

2.3 (0.5)

2.8 (0.5)

-0.8 (0.5)

Abbreviations: AWARD = Assessment of Weekly AdministRation of LY2189265 in Diabetes; DULA = dulagultide; GI = Gastrointestinal; LSM = least squares mean; Q1 = first quartile; Q3 = third quartile; SITA = Sitagliptin; U/l = units per liter.

a Data presented as n (%) unless otherwise indicated.

b <54 mg/dL cutoff, 1-year adjusted rate.

  

References

1. Weinstock RS, Guerci B, Umpierrez G, et al. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study. Diabetes Obes Metab. 2015;17(9):849-858. http://dx.doi.org/10.1111/dom.12479

2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Glossary

AE = adverse event

AWARD = Assessment of Weekly AdministRation of LY2189265 in Diabetes

GI = gastrointestinal

T2DM = type 2 diabetes mellitus

TEAE = treatment-emergent adverse event

Datum fӧr senaste ӧversyn 2018 M04 25


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Skriv din fråga till oss